Novo Nordisk has received accelerated approval for Wegovy, the first GLP-1 therapy for metabolic dysfunction-associated steatohepatitis (MASH).
Raluca Ioana Draghici
International
www.shutterstock.com
Always see our news on Google
The FDA has fast-tracked approval of Novo Nordisk's drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), affecting 5% of US adults. This is the first GLP-1 class therapy approved for MASH aimed at improving liver function. Preliminary studies have shown promising results, and Novo Nordisk has already applied for approval in Europe and Japan, expecting final trial results in 2029.
Sources
Latest News
13:47
Europol tracks networks that order assassinations remotely after five arrests in three countries
13:42
Nava turcească lovită de dronă în Marea Neară s-a scufundat: 11 marinari au fost salvați / Doi membri ai echipajului sunt morți
13:42
Grupul Kompus deschide pe 7 octombrie cea de-a șasea ediție a expoziției anuale, în Cartierul Armenesc din București.
13:41
Premierul Japoniei promite o relaţie stabilă cu China, un „vecin important”
13:40
Nicușor Dan promulgates the law for rapid intervention in the case of bears. Nearly 1,000 specimens can be harvested annually
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
